An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Trial Profile

An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Lutetium-177-DOTA-satoreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Ipsen
  • Most Recent Events

    • 17 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 30 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2017.
    • 28 Dec 2016 Planned End Date changed from 1 Dec 2019 to 1 May 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top